✕
English繁體中文
(Traditional Chinese)
HISTORY
Where we began and why there’s no end in sight.

MediBeacon, in a management buyout in 2012, acquired technology from Mallinckrodt/Covidien. Since then, the company has conducted numerous clinical studies focused on the transdermal detection of proprietary fluorescent agents as a means to measure physiological function.

The company’s intellectual property has expanded substantially and now includes over 35 granted US patents, which cover composition of matter of the company’s pharmaceuticals, as well as algorithms and methods related to the transdermal detection of these patented fluorescent agents.

“Fluorescence techniques could be advantageously applied to humans, and results of human trials are eagerly awaited.”

– American Journal of Physiology: Renal Physiology 2011
INDUSTRY INVESTMENT

In 2015, Pansend Life Sciences of HC2 Holdings, Inc. (NYSE MKT: HCHC) became the largest equity investor in MediBeacon. In 2019, MediBeacon entered into a $30 million investment and exclusive commercialization partnership in Greater China with Huadong Medicine Co., Ltd. Huadong is a leading China-based pharmaceutical company listed on the Shenzhen Stock Exchange.

MediBeacon’s fluorescent agent platform for use in physiological function monitoring has important applications in kidney health, gastrointestinal health, and beyond.
MEDIBEACON TIMELINE
Making technology that is making medical history.*
  • The Transdermal GFR Measurement System (TGFR) is poised to begin its pivotal clinical study in the U.S. and Europe.
  • First-in-human studies are underway to establish the feasibility of fluorescent tracer agent-based systems to quantify the permeability of the gastrointestinal tract in patients with active Crohn’s Disease.
  • The Centers for Medicare & Medicaid Services implement a dedicated ICD-10 code for use with the TGFR (XT25XE5 - Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology, Group 5)
  • MediBeacon enters into a $30 Million investment and exclusive commercialization partnership with Huadong Medicine headquartered in greater China.
  • MediBeacon obtains ISO 13485:2016 Recertification.
  • Introduction of the Transdermal Mini GFR Monitor for preclinical use.
  • FDA grants “Breakthrough Device Status” for MediBeacon’s Transdermal GFR Measurement System.
  • Publication of MediBeacon gut permeability research in Nature Publication – Scientific Reports.
  • Clinical studies demonstrating TGFR use completed on patients with impaired kidney function.
  • MediBeacon presents gastrointestinal permeability research at Digestive Disease Week in Chicago.
  • MediBeacon acquires Mannheim Pharma & Diagnostics (Preclinical business).
  • NIH awards grant to study fluorescent technology for use in ocular angiography.
  • A follow-on grant from the Bill & Melinda Gates Foundation funds MediBeacon continued gastroenterology collaboration with Washington University School of Medicine.
  • Investment in patented fluorescent tracer agents for use in numerous potential medical applications outside of nephrology increases.
  • MediBeacon closes on a $22.4 million staged financing with Pansend Life Sciences, LLC.
  • Results of initial TGFR clinical studies presented at American Society of Nephrology (ASN) Kidney Week.
  • Initial TGFR clinical studies are completed at the University of Maryland.
  • MediBeacon in collaboration with Washington University begins pursuing the use of fluorophore technology in gastroenterology. The work is funded by an initial grant from the Bill & Melinda Gates Foundation.
  • MediBeacon begins human clinical studies at the University of Maryland.
  • MediBeacon acquires outright all technology, market research, patent estate and other related assets from Mallinckrodt.
  • First quarter 2012, U.S. patent issued to MediBeacon for Lumitrace™ (relmapriazin).

At MediBeacon, we measure our success in our ability to create measurable differences that impact global health. Evidence of our advances can be found in the numerous issued global patents.

United States
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 735-0968

Germany
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
华东医药股份有限公司
联系电话：4008-269-985
+86-(0)571-89908581
邮政编码：310011
地址：中国浙江省杭州市拱墅区莫干山路866号
邮箱：info@eastchinapharm.com

科学技术 工作原理 研发技术平台 产品线 专利权 临床前动物实验研究 临床研究 专注领域 肾脏疾病研究 胃肠道疾病研究 眼科研究 外科技术 研究发现 投资者 为什么重要 公司概述 数字
应用文献 MediBeacon文献 临床前动物实验研究文献 行业文献 公司 历史 科学家 质量承诺 新闻/媒体 华东新闻 联系我们 获取最新资讯 投资者 常见问题

* MediBeacon 的各个产品线均处于临床开发的不同阶段，尚未批准用于人体。

经皮GFR监测系统（TGFR）用于检查肾功能受损或正常人的肾小球滤过率（GFR），本网站使用的文献中涉及到的“肾脏功能”或者“肾功能”均指GFR检测

会议预告 | 经皮无创监测小动物肾功能，这样的技术将为研发工作带来怎样的改变？
  长期以来，测量肾功能的标准科研方法是收集血液或尿液样本并利用复杂的实验室分析设备来测量每个样本中的Marker浓度。这种方法不仅费时费力，而且多次抽血会对动物造成损伤。 科研工作者一直期待能有一种无创和精确的肾脏功能检测方法，在避免上述缺憾的同时，还能很好地满足基础医学和新药研发的相关需求。而今来自美国 MediBeacon的小动物经皮肾小球滤过率监测技术（Transdermal GFR technology）将这一切变为了可能。 目前该系统已于2020年在中国正式上市，全球已有超过150家学术中心、40家制药公司（占全球Top 20药企的75%）、11个CRO公司采用这一技术，来进行高血压肾病、糖尿病肾病、免疫与炎症、代谢与调节、药理毒理、新药研发等基础研究，已发表文献和海报摘要250多篇。
- 了解更多
华东医药携Medibeacon参展2020慕尼黑上海分析生化展圆满收官！
  11月16日，备受瞩目的实验室行业灯塔展会——慕尼黑上海分析生化展（以下简称analytica China 2020）在上海新国际博览中心E2至E7馆盛大揭幕。作为今年亚洲乃至全球规模庞大的实验室行业盛会，analytica China
- 了解更多

Terms and Conditions | Privacy Policy | © 2021 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.